Furthermore, SARS-CoV-2 S-pseudotyped infections in MDMs were blocked by treatment with a cathepsin inhibitor (E64D) but not a TMPRSS2 inhibitor (Camostat) (Fig 1D), suggesting that SARS-CoV-2 S facilitates endosomal viral entry into ACE2-deficient MDMs. The gene discussed is ACE2; the disease is infection.